Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 6/20 | 0.52 |
| ▸ | TACR3 | P29371 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895783 | 0.91 | BDKRB1 (0.50) | TACR2TACR3KCNH2KDM4EALDH1A1 | |
| SCHEMBL4884299 | 0.89 | DHODH (0.50) | TACR2TACR3KCNH2KDM4EALDH1A1 | |
| SCHEMBL5945356 | 0.83 | TACR3 (0.55) | TACR2TACR3KCNH2OPRM1 | |
| SCHEMBL5635725 | 0.82 | TACR3 (0.74) | TACR2TACR3OPRM1 | |
| SCHEMBL5945365 | 0.80 | TACR3 (0.57) | TACR2TACR3KCNH2OPRM1 | |
| SCHEMBL4892659 | 0.80 | DHODH (0.44) | TACR2TACR3 | |
| SCHEMBL4896249 | 0.79 | TACR3 (0.63) | TACR2TACR3OPRM1 | |
| SCHEMBL4896258 | 0.79 | TACR3 (0.63) | TACR2TACR3OPRM1 | |
| SCHEMBL2372595 | 0.77 | SMN1; SMN2 (0.54) | TACR2TACR3KDM4EALDH1A1POLB | |
| SCHEMBL14115125 | 0.77 | SMN1; SMN2 (0.54) | TACR2TACR3KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | TACR1, TACR2, KCNA3 | TACR2 2/4885TACR3 10/4885KCNH2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.